News & Investors

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jun 23, 2017
STAMFORD, Conn., June 23, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the U.S. Food and Drug Administration (FDA) h...
Jun 21, 2017
- Trial will continue to test two doses of CR845 and aims to enroll up to 450 patients - - Both doses of CR845 well tolerated - - Trial completion expected in the fourth quarter of 2017 - STAMFORD, Conn., June 21, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commerci...
May 17, 2017
Dr. Joseph Stauffer to deliver opening remarks and discuss kappa opioid receptor agonists as a novel approach to acute and chronic pain managementDr. Stauffer serves as co-chair and on the event's Scientific Advisory Board STAMFORD, Conn., May 17, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on ...
May 12, 2017
STAMFORD, Conn., May 12, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a key opinion leader (KOL) b...
May 4, 2017
- Reported statistically significant positive top-line results from Part A of Phase 2/3 trial for I.V. CR845 in chronic kidney disease (CKD)-associated pruritus -  - Completed public offering of common stock, raising net proceeds of $86.5 million - - Conference call today at 4:30 p.m. ET -STAMFORD, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Cara ...
Apr 27, 2017
STAMFORD, Conn., April 27, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live...
Apr 24, 2017
STAMFORD, Conn., April 24, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced summary results from its Phase 1 safety trial sho...
Apr 5, 2017
STAMFORD, Conn., April 05, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the closing of its underwritten public offering of 5,...
Mar 30, 2017
STAMFORD, Conn., March 30, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the pricing of its underwritten public offering of 4,...
Mar 29, 2017
STAMFORD, Conn., March 29, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has commenced an underwritten public offering...
Mar 28, 2017
STAMFORD, Conn., March 28, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will pres...
Mar 28, 2017
Met primary endpoint with 68% reduction in worst itching scores versus placebo after eight-week treatment period (p...
Mar 13, 2017
STAMFORD, Conn., March 13, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it will present at two upcoming medical meetings...
Mar 9, 2017
STAMFORD, Conn., March 09, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended Dec...
Mar 2, 2017
STAMFORD, Conn., March 02, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live...
Page:
2
...
9
Next Last
 
= add release to Briefcase